Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Inflammatory Bowel Disease

Therapeutic area intelligence for Inflammatory Bowel Disease with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
8
Catalysts
0
Companies
0

Companies

No related entities indexed yet.

Assets

Nurosym →
Olympus →
Ustekinumab →
Vitamin →

Recent signals(8)

ClinicalJuly 25, 2026

Study on VR-Directed Therapy for Pain Management in IBD Patients

A study is underway to evaluate the feasibility and acceptability of VR-directed brain-gut behavioral therapy for hospitalized IBD patients.

ClinicalJuly 18, 2026

IL-37 Shows Protective Role in Inflammatory Bowel Disease and Colitis-Associated Cancer

IL-37 is upregulated in inflammatory bowel disease and colitis-associated cancer, exerting protective anti-inflammatory effects.

ClinicalJuly 10, 2026

Comparative Study of AI vs Narrow Band Imaging for IBD Cancer Surveillance

A study is comparing AI-assisted detection with narrow-band imaging for identifying dysplasia in IBD patients during colonoscopy.

ClinicalJuly 9, 2026

Trial on Text-Based Monitoring for IBD Outcomes and Patient Empowerment

A clinical trial is assessing the impact of text messaging on disease management and outcomes in IBD patients.

ClinicalJune 30, 2026

Vitamin D Supplementation May Improve Iron Status in IBD Patients

A pilot study is evaluating the impact of vitamin D supplementation on iron parameters in adults with inflammatory bowel disease.

ClinicalJune 26, 2026

Study on Ustekinumab for IBD Patients Switching from Anti-TNFα Due to Psoriasis

A study is investigating the outcomes of children with Crohn's disease or ulcerative colitis who switch from anti-TNFα therapy to ustekinumab due to paradoxical psoriasis.

ClinicalJune 23, 2026

Study on Dual-Target Combination Therapies for Inflammatory Bowel Disease Initiated

A study is underway to evaluate the effectiveness and safety of dual-target combination therapies in IBD patients.

ClinicalJune 21, 2026

Pilot Study on Non-Invasive Vagus Nerve Stimulation in IBD Remission

The VIBRANT-IBD study is assessing the feasibility of non-invasive vagus nerve stimulation in IBD patients in remission.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Inflammatory Bowel Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.